Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …
aggregated. The objective of this study was to perform a systematic review and meta …
COVID-19 and cancer: current challenges and perspectives
Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …
[PDF][PDF] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a …
Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
[HTML][HTML] Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer …
Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …
Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
M Treskova-Schwarzbach, L Haas, S Reda, A Pilic… - BMC medicine, 2021 - Springer
Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …
Infectious Diseases Society of America guidelines on the diagnosis of coronavirus disease 2019
IDSA Disclaimer As of the time of this publication, updates have been made to IDSA's
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …
Natural history of COVID-19 and therapeutic options
P Gautret, M Million, PA Jarrot… - Expert review of …, 2020 - Taylor & Francis
Introduction: COVID-19 presents benign forms in young patients who frequently present with
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …
Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a …
Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …
death in patients with cancer. However, the implications of certain tumor types, treatments …
Outcomes of the SARS-CoV-2 omicron (B. 1.1. 529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the …
Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …